Nevanac (Nepafenac)

Nepafenac, the active ingredient in Nevanac, is a NSAID presented as an ophthalmic solution for ocular use. It is employed to manage post‑operative inflammation and pain following cataract surgery and other ocular inflammatory conditions in adult patients. The drug works by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis within eye tissues.

GNH USA supplies Nevanac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across multiple markets.

Nevanac is an ophthalmic NSAID used to treat inflammation and pain in ocular surgery and disease contexts. - Cataract surgery: reduces inflammation and pain after the procedure. - Ocular inflammation: controls inflammatory response in the eye. - Post‑operative ocular pain: provides analgesia following eye surgeries.

Adverse reactions may occur with any ophthalmic medication. Patients should be aware of both common and serious potential effects.

Common Side Effects: - Eye irritation: mild burning or stinging after instillation. - Redness: conjunctival hyperemia. - Blurred vision: temporary visual disturbance. - Tearing: increased lacrimation. - Foreign body sensation: feeling of something in the eye. - Photophobia: light sensitivity.

Serious or Rare Side Effects: - Corneal ulceration: breakdown of corneal epithelium. - Increased intra‑ocular pressure: may exacerbate glaucoma. - Severe allergic reaction: swelling, itching, or rash around the eye. - Vision loss: sudden decrease in visual acuity. - Persistent eye pain: may indicate deeper ocular injury. - Endophthalmitis: intra‑ocular infection.

Before prescribing Nevanac, clinicians should consider several safety factors. - Assess for ocular infection: avoid use if active infection is present. - Hypersensitivity: discontinue if patient shows allergic reaction to nepafenac or other NSAIDs. - Corneal disease: use with caution in patients with compromised corneal integrity. - Intra‑ocular pressure: monitor patients with glaucoma or ocular hypertension. - Concurrent ocular NSAIDs: avoid simultaneous use to reduce risk of corneal toxicity. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Nevanac may interact with other ophthalmic or systemic agents; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Concurrent ophthalmic NSAIDs: increased risk of corneal toxicity. - Systemic anticoagulants: potential for enhanced ocular bleeding.

Moderate Interactions (Monitor Closely): - Corticosteroid eye drops: additive anti‑inflammatory effect, monitor healing. - Contact lens wear: may cause discomfort or reduced drug efficacy. - Prostaglandin analogs for glaucoma: monitor intra‑ocular pressure changes. - Systemic NSAIDs: watch for additive systemic side effects. - Topical anesthetics: may increase corneal irritation.